Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Board appointments at Algeta

This article was originally published in Scrip

Executive Summary

Algeta (Norway), an oncology-focused company developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform, has elected Dr Judith Hemberger and Dr Kapil Dhingra non-executive directors. Dr Hemberger has more than 30 years' pharmaceutical and biotech industry experience, having most recently served as a venture partner at Nomura Phase4 Ventures and interim CEO of Zosano Pharma. Before that Dr Hemberger was co-founder, executive vice-president and chief operating officer of Pharmion. Dr Dhingra was formerly vice-president, head of the oncology disease biology leadership team, and head of oncology clinical development at Roche. Before that, he was clinical and senior clinical research physician at Lilly.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel